{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:45:03Z","timestamp":1774572303190,"version":"3.50.1"},"reference-count":18,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>To characterize the prescribing trends and clinical outcomes related to azithromycin (AZI) among children hospitalized for critical asthma (CA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We performed a multicenter, retrospective cohort study using the Pediatric Health Information Systems registry of children 3 to 17 years of age hospitalized in a PICU for CA from January 2011 to December 2022. We excluded for alternative indications for AZI (eg, atypical pneumonia, B. pertussis infection, acute otitis media, acute sinusitis, pharyngitis\/tonsillitis, and urethritis). The primary outcome was AZI prescribing rate by hospital and calendar year (trends assessed by Joinpoint regression). Cohorts with and without AZI exposure were further characterized by demographics, CA treatments, and inpatient outcomes using descriptive and comparative (ie, \u03c72 and Wilcoxon rank tests) statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of the 47\u2009797 children studied, 9901 (20.7%) were prescribed AZI with a downward annual trend noted from 34.7% in 2011% to 12.4% in 2022 (\u22121.7% per year, R2 = 0.91). Median institutional AZI prescribing rate was 19.2% (interquartile range [IQR] 11.7%\u201328%; total range 5.6%\u201360%). Compared with children not prescribed AZI, those prescribed AZI were older (median 8.3 [IQR 5.7\u201311.6] vs 7.3 [4.9\u201310.8] years, P &amp;lt; .001) and experienced a more severe clinical trajectory with greater rates of bilevel positive airway pressure ventilation (19.7% vs 12.6%, P &amp;lt; .001), invasive ventilation (22.1% vs 13.5%, P &amp;lt; .001), extracorporeal life support (0.8% vs 0.1%, P &amp;lt; .001), and median length of stay (4 [IQR 3\u20136] vs 3 [IQR 2\u20134] days, P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Between 2011 and 2022, 20.7% of children hospitalized for CA were prescribed AZI notwithstanding the absence of trial-derived efficacy or safety data for this indication and population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/hpeds.2023-007627","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:05:39Z","timestamp":1715933139000},"page":"e254-e259","source":"Crossref","is-referenced-by-count":5,"title":["Azithromycin for Pediatric Critical Asthma: A Multicenter Retrospective Cohort Study"],"prefix":"10.1542","volume":"14","author":[{"given":"Alexa R.","family":"Roberts","sequence":"first","affiliation":[{"name":"aDivisions of Pediatric Critical Care Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Vallabhaneni","sequence":"additional","affiliation":[{"name":"bDepartment of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Russi","sequence":"additional","affiliation":[{"name":"aDivisions of Pediatric Critical Care Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tisha L.","family":"Spence","sequence":"additional","affiliation":[{"name":"aDivisions of Pediatric Critical Care Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer W.","family":"Leiding","sequence":"additional","affiliation":[{"name":"cAllergy and Immunology, Johns Hopkins All Children\u2019s Hospital, St Petersburg, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Sochet","sequence":"additional","affiliation":[{"name":"aDivisions of Pediatric Critical Care Medicine"},{"name":"bDepartment of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, Florida"},{"name":"dDepartment of Anesthesia and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2024060102523924200_B1","article-title":"AsthmaStats: uncontrolled asthma among children with current asthma, 2018\u20132020","author":"Centers for Disease Control and Prevention"},{"key":"2024060102523924200_B2","first-page":"373","volume-title":"National Asthma Education and Prevention Program (NAEPP): Expert Panel Report-3 (epr-3)","author":"National Heart, Lung, and Blood Institute","year":"2012"},{"issue":"3","key":"2024060102523924200_B3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1542\/peds.2011-3318","article-title":"The Joint Commission children\u2019s asthma care quality measures and asthma readmissions","volume":"130","author":"Fassl","year":"2012","journal-title":"Pediatrics"},{"key":"2024060102523924200_B4","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1542\/peds.2008-2233C","article-title":"Status of childhood asthma in the United States, 1980\u20132007","volume":"123","author":"Akinbami","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"2024060102523924200_B5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1164\/ajrccm.156.1.9612065","article-title":"Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells","volume":"156","author":"Takizawa","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2024060102523924200_B6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2024060102523924200_B7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culi\u0107","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2024060102523924200_B8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/00325481.2017.1285677","article-title":"Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician","volume":"129","author":"Cramer","year":"2017","journal-title":"Postgrad Med"},{"issue":"11","key":"2024060102523924200_B9","first-page":"CD002997","article-title":"Macrolides versus placebo for chronic asthma","volume":"11","author":"Undela","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"10095","key":"2024060102523924200_B10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomized, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"2024060102523924200_B11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicenter, randomized, double-blind, placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"11","key":"2024060102523924200_B12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/jamainternmed.2016.5664","article-title":"Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial","volume":"176","author":"Johnston","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2024060102523924200_B13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.chest.2022.02.025","article-title":"Azithromycin for poorly controlled asthma in children: a randomized controlled trial","volume":"161","author":"Ghimire","year":"2022","journal-title":"Chest"},{"issue":"5","key":"2024060102523924200_B14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/02770903.2019.1590590","article-title":"Azithromycin treatment in children hospitalized with asthma: a retrospective cohort study","volume":"57","author":"Douglas","year":"2020","journal-title":"J Asthma"},{"issue":"1","key":"2024060102523924200_B15","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"2024060102523924200_B16","first-page":"118","article-title":"Understanding the immunology of asthma: pathophysiology, biomarkers, and treatments for asthma endotypes","volume":"36","author":"Gans","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"2024060102523924200_B17","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.33549\/physiolres.934398","article-title":"Biomarkers of bronchial asthma","volume":"69","author":"Kunc","year":"2020","journal-title":"Physiol Res"},{"issue":"1","key":"2024060102523924200_B18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/PCC.0000000000003347","article-title":"Wide institutional variability in the treatment of pediatric critical asthma: a multicenter retrospective study","volume":"25","author":"Rogerson","year":"2024","journal-title":"Pediatr Crit Care Med"}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/14\/6\/e254\/1658941\/hpeds.2023-007627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/14\/6\/e254\/1658941\/hpeds.2023-007627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:52:59Z","timestamp":1717210379000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/14\/6\/e254\/197302\/Azithromycin-for-Pediatric-Critical-Asthma-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2023-007627","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"value":"2154-1663","type":"print"},{"value":"2154-1671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}